World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
32746
World Ranking
13961
National Ranking
460

Jeff Szer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jeff Szer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 620 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jeff Szer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jeff Szer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jeff Szer is a researcher affiliated with the Peter MacCallum Cancer Centre in Australia. Their scholarly work is concentrated within the field of Medicine, with particular emphasis on Hematology, Immunology, and Genetics. The subfields that feature prominently in their research include Physiology and Public Health, Environmental and Occupational Health.

The main topics addressed in their publications reflect a focus on blood and immune system-related medical issues. These topics include:

  • Complement system in diseases
  • Hematopoietic Stem Cell Transplantation
  • Blood groups and transfusion
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Acute Myeloid Leukemia Research
  • Lysosomal Storage Disorders Research
  • Renal Diseases and Glomerulopathies

Jeff Szer has contributed to a variety of scientific articles across multiple respected journals. Frequent publication venues for their work include:

  • Internal Medicine Journal
  • Blood
  • Haematologica
  • The Lancet Haematology
  • Bone Marrow Transplantation

Their recent papers cover notable studies in the areas of hematology and treatment of blood-related diseases, including:

  • "Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease", 2020, New England Journal of Medicine
  • "Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria", 2021, New England Journal of Medicine
  • "One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors", 2021, Haematologica
  • "Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance", 2020, The Medical Journal of Australia
  • "Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria", 2020, Haematologica

The researcher frequently collaborates with other scientists, with the most common coauthors being:

  • Régis Peffault de Latour
  • Mahmoud Aljurf
  • Morag Griffin
  • Dietger Niederwieser
  • Mickey Koh

Best Publications

  • The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Neal S. Young;Jörg Schubert;Robert A. Brodsky

  • Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

    W.P. Sheridan;R.M. Fox;C.G. Begley;D. Maher

  • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Ian Parkinson

  • Hematopoietic stem cell transplantation: a global perspective

    Alois Gratwohl;Helen Baldomero;Mahmoud Aljurf;Marcelo C. Pasquini

  • Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

    Robert Zeiser;Nikolas von Bubnoff;Jason Butler;Mohamad Mohty

  • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Petra Muus;Ulrich Dührsen;Antonio M. Risitano

  • Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

    Navneet S. Majhail;Navneet S. Majhail;J. Douglas Rizzo;Stephanie J. Lee;Mahmoud Aljurf

  • A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.

    JF Bishop;JP Matthews;Ga Young;J Szer

  • A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers

    Simon J Stanworth;Lise J Estcourt;Lise J Estcourt;Gillian Powter;Brennan C Kahan

  • One million haemopoietic stem-cell transplants: a retrospective observational study

    Alois Gratwohl;Marcelo C Pasquini;Mahmoud Aljurf;Yoshiko Atsuta

  • Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

    Peter Hillmen;Petra Muus;Alexander Roth;Modupe O. Elebute

  • A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia

    Gerhard Heil;Dieter Hoelzer;Miguel A. Sanz;Klaus Lechner

  • Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

    Dietger Niederwieser;Helen Baldomero;Jeff Szer;Michael Gratwohl

  • All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

    Harry J. Iland;Harry J. Iland;Ken Bradstock;Ken Bradstock;Shane G. Supple;Alberto Catalano

  • Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.

    Mats Brune;Sylvie Castaigne;John Catalano;Kurt Gehlsen

  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

    Robert J. Soiffer;Haesook T. Kim;Joseph McGuirk;Mitchell E. Horwitz

  • Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

    Austin G. Kulasekararaj;Anita Hill;Scott T. Rottinghaus;Saskia Langemeijer

  • Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

    Brian J P Huntly;Alistair G Reid;Anthony J Bench;L J Campbell

  • Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

    Norbert Schmitz;Meral Beksac;Dirk Hasenclever;Andrea Bacigalupo

  • Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

    A Grigg;C G Begley;C A Juttner;J Szer

Frequent Co-Authors

David Ritchie
David Ritchie Peter MacCallum Cancer Centre
Andrew Grigg
Andrew Grigg Austin Hospital
Kenneth F. Bradstock
Kenneth F. Bradstock Westmead Hospital
Mahmoud Aljurf
Mahmoud Aljurf King Faisal Specialist Hospital & Research Centre
John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Monica A. Slavin
Monica A. Slavin Peter MacCallum Cancer Centre
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
Hubert Schrezenmeier
Hubert Schrezenmeier University of Ulm
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but looking for a more flexible or alternative career path, many accredited online degrees offer expanded opportunities in healthcare. For those who prefer administrative roles, exploring the medical billing and coding schools online can provide a streamlined route into healthcare systems with the potential for remote work and career growth.

Nursing also remains a highly in-demand field. If you want to advance without traditional entrance exams, consider lpn to rn programs without teas test requirements to continue your educational journey. For those aspiring to move into leadership, the best online healthcare administration degree programs prepare graduates for management and executive positions within hospitals and clinics.

Registered nurses aiming for advanced practice should explore rn to fnp bridge programs, which enable a focused transition to becoming a Family Nurse Practitioner. These online pathways provide flexible options to earn qualifications while balancing work and family life.

Best Scientists Citing Jeff Szer

Trending Scientists

Recently Published Articles